Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. director reports open-market stock purchase
A Teladoc Health, Inc. director filed a Form 4 reporting the purchase of 10,000 shares of the company’s common stock. The transaction took place on 11/14/2025 at a price of $6.94 per share, resulting in beneficial ownership of 10,000 shares following the trade, held directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that the reporting person adopted on August 15, 2025. Rule 10b5-1 plans are pre-arranged trading programs intended to allow insiders to buy or sell shares according to preset instructions.
Teladoc Health (TDOC): Schedule 13G/A update on ownership
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported beneficial ownership of 5,795,178 Teladoc common shares, representing 3.3% of the class as of September 30, 2025. The filers report shared voting and dispositive power over 5,795,178 shares and no sole voting or dispositive power.
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Teladoc. This amendment formalizes current holdings and roles among the reporting persons, including Mr. Cohen’s indirect control of the reporting entities.
Teladoc Health (TDOC) reported Q3 2025 results showing revenue of $626.4 million versus $640.5 million a year ago, reflecting softer BetterHelp contributions partly offset by Integrated Care growth. The company posted a net loss of $49.5 million compared with a $33.3 million loss last year, including a $12.6 million goodwill impairment tied to an Integrated Care acquisition.
For the first nine months, revenue was $1.89 billion versus $1.93 billion, with net loss improving to $175.2 million from $952.8 million due to last year’s large goodwill charge. Q3 segment revenue was $389.5 million for Integrated Care and $236.9 million for BetterHelp. Adjusted EBITDA was $69.9 million, down from $83.3 million.
Cash and equivalents were $726.2 million, supported by operating cash flow of $206.6 million year‑to‑date. Teladoc repaid $550.0 million of Livongo 2025 notes and $0.6 million of 2025 notes; $1.0 billion of 2027 notes remain outstanding. The company established a new $300 million revolving credit facility and had $297.8 million available at quarter end.
Teladoc Health, Inc. furnished an 8‑K to announce it issued a press release with its third‑quarter 2025 financial results. The press release is attached as Exhibit 99.1 and dated October 29, 2025.
The company states the information is being furnished, not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor incorporated into Securities Act filings unless specifically referenced.
Teladoc Health (TDOC) announced preliminary Q3 2025 results, noting they are unaudited and subject to change as the company completes its closing process. The company also stated it continues to expect its consolidated full-year 2025 results to be consistent with the outlook range disclosed on July 29, 2025. A press release with additional details, including non-GAAP measures and reconciliations, was furnished as Exhibit 99.1.
The company also disclosed a leadership change: Chief Financial Officer Mala Murthy informed Teladoc of her resignation effective November 21, 2025. She is expected to present on the company’s third-quarter conference call on October 29, 2025. The company indicated her decision was for personal reasons and not due to any disagreement regarding operations, policies, or practices. The information in the press release and items referenced was furnished, not filed.
Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc. (TDOC), reported the vesting and partial sale of restricted stock units. On 10/01/2025 8,333 restricted stock units converted to 8,333 shares of common stock. On 10/02/2025 he sold 2,972 shares at $7.885 per share to cover tax withholding, leaving 5,361 shares beneficially owned following the sale. The filing notes the RSU grant of 25,000 units on 10/01/2024 with one-third vesting on the first anniversary and the remainder vesting in eight substantially equal quarterly installments.
Jason Eric Evans, a director of Teladoc Health, Inc. (TDOC), reported transactions dated 09/19/2025 on Form 4. The filing shows acquisition of 1,016 restricted stock units that convert one-for-one into common shares, and the reporting person acquired 1,016 shares of common stock on the same date. After the transactions, the reporting person beneficially owned 8,129 shares of common stock and 4,066 derivative securities representing underlying common stock. The RSUs were part of a grant originally awarded on 09/20/2023 totaling 12,195 RSUs with a stated vesting schedule. The form is signed by an attorney-in-fact on 09/22/2025.
Jason Eric Evans, a director of Teladoc Health, Inc. (TDOC), reported transactions dated 09/19/2025 on Form 4. The filing shows acquisition of 1,016 restricted stock units that convert one-for-one into common shares, and the reporting person acquired 1,016 shares of common stock on the same date. After the transactions, the reporting person beneficially owned 8,129 shares of common stock and 4,066 derivative securities representing underlying common stock. The RSUs were part of a grant originally awarded on 09/20/2023 totaling 12,195 RSUs with a stated vesting schedule. The form is signed by an attorney-in-fact on 09/22/2025.
Teladoc Health insider transactions by Charles Divita III: On 09/10/2025, 39,160 restricted stock units vested and were treated as an acquisition (one-for-one conversion to common stock), increasing his reported beneficial ownership. On 09/11/2025 he sold 16,787 shares to cover tax withholding at an average price of $7.5913, leaving 179,014 shares beneficially owned according to the Form 4. The filing notes a grant on June 10, 2024 of 469,924 RSUs that vest over time, with one-third vesting on the first anniversary and the remainder in eight equal quarterly installments.
Teladoc Health (TDOC) filed a Form 144 reporting a proposed sale of 16,787 common shares held at Fidelity Brokerage Services with an aggregate market value of $127,435.15. The filing shows an approximate sale date of 09/11/2025 on the NYSE. The shares were acquired the prior day, 09/10/2025, through restricted stock vesting from the issuer and were granted as compensation. The filer reports no securities sold by the same person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Teladoc Health insider transactions by Fernando M. Rodrigues Reporting person Fernando M. Rodrigues, President of BetterHelp, reported restricted stock unit vesting and subsequent sales. On 08/29/2025, 5,491 and 1,041 restricted stock units were deemed acquired and converted one-for-one into shares. On 09/02/2025, 2,383 shares were sold at $7.585 per share to cover tax withholding related to the RSU vesting. On 09/03/2025, an additional 4,149 shares were sold at $7.59 per share under a Rule 10b5-1 plan adopted November 18, 2024 and amended November 27, 2024. Following these transactions the reporting person beneficially owned 27,457 shares and had 6,252 shares outstanding from recent grants.